Zydus Lifesciences Subscribes to Equity Shares of Torrent Urja 25 in Phased Investment
Zydus Lifesciences Limited, along with its subsidiaries, successfully consummated the subscription of equity shares of Torrent Urja 25 Private Limited in phases, cementing its commitment to strategic investments aligned with Environmental, Social, and Governance (ESG) principles and carbon neutrality objectives.The investment strategy involved multiple tranches, with the Company detailing its stake in Torrent Urja 25. Zydus Lifesciences initially informed stakeholders of its plan to subscribe shares through Share Subscription and Shareholders' Agreements (SSSA).
The investment was executed across multiple tranches, concluding the transaction on May 19, 2026.
The investment details are as follows:
| Tranche | Investment Amount | Number of Shares Subscribed | Percentage of Paid-up Share Capital |
|---|---|---|---|
| Tranche 1 | Rs. 38.65 million | 38,64,792 | 22.06% |
| Tranche 2, 3, and 4 | Rs. 90.18 million | 90,17,848 | 22.06% |
Zydus Lifesciences and its various subsidiaries made the initial investment of Rs. 38.65 million for the subscription of 38,64,792 equity shares under Tranche 1. Subsequently, on May 19, 2026, the Company completed the investment of the remaining amount of Rs. 90.18 million for the subscription of 90,17,848 equity shares under Tranche 2, 3, and 4.
The overall transaction of subscribing to shares of Torrent Urja 25 was officially consummated on May 19, 2026. The investment underscores the Company’s strategic objective of achieving carbon neutrality, demonstrating a commitment to ESG principles.
ZYDUSLIFE Stock Price Movement
Shares of Zydus Lifesciences Limited are edging higher to ₹1060.15 as of 12:56 PM, gaining 4.05% in live trading. The stock registers a critical 52-week high of ₹1093.65 and sees significant activity, with 11.43 million shares traded in the current session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.